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Abstract  
 
Background and aims. Beta cell destruction in human type 1 diabetes occurs through the interplay 
of genetic and environmental factors and is mediated by immune cell infiltration of pancreatic 
islets. The aim of the present study was to investigate the role of different inflammatory cells in the 
type 1 diabetes insulitis scenario. Materials and Methods. Pancreatic samples were obtained from 
the glands of 7 T1D, 7 T2D and 7 ND organ donors, with similar clinical features, and processed by 
standard electron microscopy techniques. Results. A greater amounts of mast cells were found to 
infiltrate pancreatic islets in human type 1 diabetic samples, than in control and type 2 diabetic 
pancreases. Evidence of mast cell degranulation was shown, and the extent of the infiltration was 
correlated with beta cell damage. In addition, we observed that histamine, the amine highly 
expressed in mast cells, could directly contribute to beta cell apoptosis by a caspase-independent 
pathway. Conclusion. These findings suggest that mast cells may be responsible, at least in part, of 
the immune-mediated beta cell alterations in human type 1 diabetes. If so, protection of beta cells in 
type 1 diabetes might benefit from inhibition of mast cell activation and degranulation. 
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Introduction 
The development and progression of type 1 diabetes results from the autoimmune destruction of 
pancreatic beta cells. Triggering of this autoimmune process occurs through the interaction between 
genetic and environmental factors (1,2), but the exact stimuli and cells participating in this process 
remain to be determined. This limited understanding of the ultimate triggers and effectors of beta 
cell death in type 1 diabetes hampers the ongoing efforts to prevent or cure the disease. In most 
patients the early stages of type 1 diabetes are associated with an immune cell infiltration 
specifically targeting the islets of Langerhans, which has been termed insulitis (1-3). Well defined 
histological criteria to detect insulitis have recently proposed, i.e. ≥15 CD45+ (leucocyte common 
antigen) cells in a minimum of three islets of approximately 150 µm in diameter (3). There is also 
agreement that the majority of infiltrating cells are of lymphocytic nature, with a predominance of 
CD3+CD8+ cells in recent-onset type 1 diabetes and an increasing contribution by B lymphocytes 
(CD20+) at later stages (4,5). Innate immunity also plays a role in this process. Thus, significant 
numbers of islet-infiltrating macrophages were observed in cases of recent onset type 1 diabetes 
(4,6), becoming the most prominent infiltrating cell type in islets devoid of insulin positive cells (5). 
More recently, the presence of neutrophils has been observed by electron microscopy and immune 
histochemical analysis in the pancreas of subjects with type 1 diabetes, both at onset and at later 
stages of the disease (7). In the present study we show that mast cells are an additional actor in the 
human type 1 diabetes islet infiltrating cell scenario. These innate immunity cells are normally 
localized near body surfaces and are consequently considered as first-line defenders against several 
environmental insults (8). Following activation through the classical IgE-dependent or the 
alternative non-IgE-dependent [via the Toll-Like Receptors –TLRs - system pathway (9)], mast 
cells play a key role in allergic reactions (8,10). They possess chemotactic as well as 
immunodulatory properties (8,11). Interestingly, a role of mast cells in autoimmune disorders such 
as Crohn’s disease, multiple sclerosis and rheumatoid arthritis has been proposed (12,13), and these 
cells may also contribute to autoimmune diabetes in experimental animal models, such as the 
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BioBreeding rat (14,15). We hereby report that mast cells infiltrate pancreatic islets during insulitis 
in human type 1 diabetes and that the extent of the infiltration correlates with beta cell damage; in 
addition, we show that histamine, the amine highly expressed in mast cells, can directly contribute 
to beta cell death via a caspase-independent apoptotic pathway.  
 
Materials and Methods 
Histology: Pancreatic samples from 7 non-diabetic, 7 type 1 and 7 type 2 diabetic multiorgan 
donors were studied (see Table 1 for details) with the approval of the local ethics committee at the 
University of Pisa. Type of diabetes was identified based on medical records, status of anti-GAD 
autoantibodies and/or morphological as well as ultrastructural appearance of pancreatic islets 
(Supplemental Figure 1). Samples for optical and electron microscopy were prepared as 
previously detailed (16). When mast cells were studied in semithin sections, staining was perfomed  
with a 1:1 mixture of tolouidin blue (1% in bidistilled water) and methylen blue (1% in bidistilled 
water). Identification of mast cells by light microscopy was mainly based on metachromatic 
staining by tolouidine blue. In some cases mast cells identification was also confirmed in paraffin-
embedded sections by the use of a mouse anti-human mast-cell triptase monoclonal antibody, clone 
G3 (Chemicon – Millipore, Billerica, MA, USA). In the electron microscopy studies, mast cell 
identification was based on their particular ultrastructural appearance, including the monolobed 
nucleus, the surface architecture composed of narrow, elongated folds, the presence of typical 
cytoplasmic granules and the absence of cytoplasmic glycogen aggregates (17). Cell counts per 
square millimeter were performed in semithin sections of pancreatic tissue. The same cells were 
counted at the electron microscope in consecutive ultrathin section, in order to allow the control of 
ultrastructural characteristics of the identified cells  (Figure 1). The count of inflammatory cells 
infiltrating pancreatic islets was performed on tissue sections where recognizable islets were 
identified and was performed in all islets. All counts were independently performed by two 
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investigators in a blinded way (samples were identified only by randomly assigned numbers). 
Apoptotic beta cells were identified based on the presence of marked chromatin condensation 
and/or blebs (Supplemental Figure 2), as reported earlier by us and others (18,19). 
Islet isolation and incubation: Isolated islets were prepared from the pancreas of 15 independent 
non-diabetic multi-organ donors (age: 69±16 yrs; gender: 8M/7F; body mass index: 26.1±3.0 
kg/m2; cause of death: 12 cardiovascular events and 3 trauma; duration of intensive care unit stay: 
3±2 days; pancreas cold ischemia time: 18±6 hours) by collagenase digestion followed by density 
gradient purification, as previously reported (19). After isolation, islets were maintained for 2–3 
days in M199 medium, containing 5.5 mmol/l glucose, supplemented with 10% serum and 
antibiotics. Then, batches of approximately 1,000 islets were cultured for 72h in M199 medium 
supplemented with 10% (vol/vol) serum and 100 U/ ml penicillin, 100 µg/ml streptomycin, 50 
µg/ml gentamicin and 750 ng/ml amphotericin B, and either with or without the addition of 100 
µmol/l histamine dihydrochloride. All the compounds were from Sigma-Aldrich (St. Louis, MO). In 
some experiments, the effect of caspase inhibition by 20 µM Z-VAD-FMK (Promega, Madison, 
Wisconsin, USA) was also tested.  
Western blot experiments: Isolated human islets were lysed in a buffer containing 40 mmol/l Tris, 
4% CHAPS, 7 mol/l urea, 2 mol/L thiourea, 1% DTT and supplemented with a protease inhibitor 
cocktail (Roche Diagnostics GmbH, Mannheim, Germany). The lysates were centrifuged to remove 
the cellular debris and the protein amount evaluated by the Bradford method. Western blot assay of 
caspase 9 and 3 activation in human islets incubated for 24h with histamine (see above) was 
performed as previously described (20). Briefly, equal amounts of total protein were heated at 
100°C for 5 min, resolved by electrophoresis in 14% SDS-polyacrylamide gel and electroblotted 
onto nitrocellulose membranes. Immunodetection was performed after overnight incubation with 
antibodies for cleaved caspase 9 and 3 (Cell Signaling, Danvers, USA), and α-tubulin (Cell 
Signaling, Danvers, USA) was used as the loading control. 
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Gene expression studies: Gene expression was determined as described (16,19). Briefly, total RNA 
was extracted using the PurelinkTM RNA mini kit (Life Technologies, Carlsbad, CA, USA) and 
quantified by absorbance at A260/A280 nm (ratio >1.9) in a NanoDrop 2000C. RNA integrity was 
assessed with an Agilent 2100 Bioanalyzer. For quantitative PCR experiments, total RNA was 
reverse-transcripted from 1 µg with SuperScript® VILO™ cDNA Synthesis Kit (Life technologies). 
The oligonucleotides of interest were obtained from assay-on-demand gene expression products 
(Life Technologies). Messenger RNA levels were quantified and normalized for β-actin in a VIIA7 
analyzer (Life Technologies). 
Mitochondrial studies. The activity of mitochondrial complex I was assayed in control and 
histamine-treated (72h) INS-1E cells (kindly provided by prof. Claes Wollheim) by using 
commercially available kits (Mitochondrial Complex I Activity Assay Kit, Millipore, Germany) 
following the instructions provided by the manufacturer. INS-1E cells were cultured in a humidified 
atmosphere containing 5% CO2 in complete medium composed of RPMI 1640 supplemented with 
10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 50 µM 2-mercaptoethanol, 2 mM 
glutamine, 10 mM HEPES, 100 U/ml penicillin, and 100 µg/ml streptomycin (21). The 
mitochondrial membrane potential (∆ψm) in control and histamine-treated INS-1 cells was 
measured cytofluorimetrically as previously described (22) with a Becton-Dickinson Facscan 
equipped with a Cell Quest software (Becton Dickinson, Franklin Lakes, New Jersey). 
Statistical analysis. Results are given as mean±SD, and differences between groups were assessed 
by the two-tailed Student’s t-test or the ANOVA test plus the Bonferroni correction, as appropriate. 
Unilinear regression analysis was also performed to evaluate correlations between selected 
parameters. A p value of less than 0.05 was considered statistically significant. 
 
Results 
Figure 2A-F reports representative images of mast cells identified by different techniques, showing 
the presence of this cell type in the non-endocrine tissue as well as in both the peri-insular and the 
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intra-insular regions. Quantification of mast cells in the non-endocrine tissue was performed by 
optical microscopy, and the count of these cells at the periphery and inside the islets was performed 
on both toluidine stained samples and by electron microscopy analysis. There were 8.2±2.5 per 
mm2  and 17.5±3.7 per mm2 mast cells respectively in control and type 1 diabetic pancreatic 
samples (p < 0.05), whereas the number of mast cells in type 2 diabetic specimens (6.6±1.3 per 
mm2) was similar to that of controls. In agreement with previous reports (4,5,23,24) our data also 
showed that lymphocyte number was significantly (p<0.05) increased only in type 1 diabetic 
samples, whereas macrophages significantly (p<0.05) increased in both type 1 and type 2 diabetic 
samples with respect to controls (Lymphocites: ND 2.8±1.3; T1D 33.2±7.3; T2d 2.9±1.0 cells per 
mm2. Macrophages: ND 5.2±1.8; T1D 12.4±1.3; T2D 18.1±3.0 cells per mm2). To assess detailed 
features of islet cells and the presence of islet infiltrating mast cells, electron microscopy was used 
(Figure 1). The number of beta cells counted was 484, 447 and 469 respectively in non-diabetic, 
type 1 and type 2 diabetic pancreases. Cells with signs of apoptosis were 0.5±0.4% in control islets, 
6.5±3.8% in type 1 diabetic islets and 4.9±1.5% in type 2 diabetic islets (both p < 0.05 vs controls). 
The proportion of islets with at least 1 mast cell was 27, 86 and 33% respectively in control, type 1 
(p < 0.05) and type 2 diabetic cases (non-significant vs controls). Mast cell number per islet was 
0.6±0.2 in control samples, 2.1±0.4 in type 1 diabetic specimens (p < 0.05), and 0.6±0.3 in type 2 
cases. In addition, in control samples all the mast cells were located at the periphery of the islets, 
whereas in type 1 diabetes cases 44% of the mast cells were within the islets. Several mast cells in 
type 1 diabetes samples appeared to be at least partially degranulated (Figure 3A-F). In type 1 
diabetic samples, number of mast cells per mm2 of pancreatic tissue was inversely correlated with 
the duration of diabetes (r = 0.82, p < 0.05), indicating attenuation of the infiltration over time; 
however, the number of islet infiltrating mast cells was not affected by duration of the disease (r = 
0.21). Interestingly, the amount of beta cells with signs of apoptosis was positively correlated with 
the number of mast cells around and in the islets (r = 0.62, p < 0.05).  
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Since histamine is one of the most abundant compounds stored by mast cells (8,13), we next tested 
if direct exposure of isolated non-diabetic human islets to this amine affects beta cell survival. After 
72h incubation the proportion of beta cells with signs of apoptosis was 1.0±0.6% in control islets 
(out of 257 beta cells counted by electron microscopy) and 6.1±2.0% (out of 306 counted beta cells) 
in islets incubated with 100 µmol/l histamine (p < 0.01). In order to investigate the mechanisms 
involved, we tested the activation of caspases 9 and 3 by Western blotting. As shown in Figure 4A, 
no difference in cleaved caspases was observed in islets exposed or not to histamine. In line with 
these observations, the presence of a caspase inhibitor did not reduce the extent of beta cell 
apoptosis following histamine exposure, as assessed by electron microscopy (Figure 4B). Of note, 
an intrinsic form of caspase-independent apoptosis has been described (25). In this case, molecules 
such as the apoptosis-inducing factor (AIF) are released from the mitochondria, translocate to the 
nucleus and mediate DNA fragmentation (25). Intriguingly, we observed a significantly increased 
expression of AIF in human islets exposed to histamine (Figure 4C). The impact of histamine on 
mitochondria was confirmed by experiments performed in insulin-producing INS-1E cells. Thus, 
we noticed that a 72h incubation with 100 µmol/l histamine caused inhibition of mitochondrial 
complex I enzyme activity (Figure 4D) (p < 0.05) and depolarization of the mitochondrial 
membrane potential as assayed by cytofluorometry (Figure 4E) (p < 0.01). 
 
Discussion 
To the best of our knowledge, mast cell infiltration of human pancreatic islets has not been 
previously described in type 1 diabetic patients. Here we show that the number of these innate 
immune system cells is increased in type 1 diabetic islets, even in patients with long-term disease (> 
20 years of diabetes), and correlates with the extent of beta cells with signs of apoptosis. These 
findings can not be explained by differences in cause of death, duration of intensive care unit stay, 
or pancreas cold ischemia time, that may affect the degree and composition of pancreas infiltration 
(26), since these variables were similar between non-diabetic and type 1 diabetic donors 
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(Supplemental Table 1). In addition, mast cell infiltration was not seen in islets of type 2 diabetic 
donors, suggesting that this feature is peculiar of type 1 diabetes. Finally, we demonstrate that 
histamine, the amine largely present in mast cells, can induce beta cell apoptosis, possibly by 
activating an intrinsic, caspase-independent apoptotic machinery. This pathway is characterized by 
mitochondrial dysfunction and release of mitochondrial proteins such as AIF, that can directly 
fragment the DNA without the need of caspase activation (25). In line with this possibility, we 
observed that histamine upregulates AIF and that the use of a caspase inhibitor does not prevent 
beta cell apoptosis. Overall, the present results are coherent with the observation of human islet 
infiltration by other cells of the innate immune system (such as neutrophils) (7) and with the 
concept that mast cells may be involved in autoimmune processes, including experimental diabetes 
(12,14,15). It is noteworthy that mast cells are present in islets obtained from long-term diabetic 
individuals (present findings), suggesting that components of the innate immune response continue 
to contribute for beta cell dysfunction and death even after putative full activation of the adaptive 
immune response. 
At the moment, it is not clear why mast cells move into the islets in type 1 diabetes. These cells are 
actively involved in the recognition of viruses and viral products (8). Since viral infections have 
been implicated in the pathogenesis of beta cell damage in type 1 diabetes (27), it is conceivable 
that the presence of a viral infection and local inflammation in the islets attract these cells. In line 
with this, mast cells are attracted to tissues expressing the chemokines CCL2, CCL3, CCL5, 
CXCL2 and CXCL 4, among others (28), and human islets exposed to viral infection (29) or to pro-
inflammatory cytokines (30,31) express high levels of these chemokines. 
Intriguingly, electron microscopy examination showed that at least some of islet-infiltrating mast 
cells are partially degranulated, indicating functional activation. Mast cells can be activated through 
the classical IgE-dependent or the alternative non-IgE-dependent activation via Toll-Like Receptors 
(TLRs)  (9). In preliminary immunohistochemical experiments we have observed that the mast cells 
in the pancreatic tissue of type 1 diabetic patients are anti-IgE negative (LM and MM, personal 
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communication), favoring the view of an activation triggered via TLRs (9).  Once activated, mast 
cells can recruit other inflammatory and immune cells (32) and/or directly damage beta cells by 
releasing histamine (as suggested by our results), both effects potentially contributing to beta cell 
dysfunction and death. In line with this hypothesis, histamine receptors are expressed in mouse and 
human pancreatic beta cells (33), and both pizotifen, an inhibitor of histamine action, and disodium-
cromoglycate, an inhibitor of mast cell degranulation, suppress diabetes development in C57B1/6J 
mice treated with multiple low doses of streptozotocin (34).  
In conclusion, the present observations suggest that mast cells are putative contributory cells for 
immune-mediated beta cell dysfunction and death in type 1 diabetes. In case these observations are 
confirmed by additional studies with larger number of samples, it will suggest that inhibitors of 
histamine action or mast cell degranulation might be considered as adjuvant therapies to protect 
beta cells in type 1 diabetes.  
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 Legend to Figures 
 
Figure 1. Consecutive semithin and ultrathin sections of a type 1 diabetic patient sample 
showing a pancreatic islets surrounded by an infiltrate containing different inflammatory 
cells (Mst = mast cell; Mc = macrophage; L = lymphocyte). The comparison between 
semithin and ultrathin consecutive sections illustrates how the identification of the different 
types of inflammatory cells at the optical microscope was further confirmed by their 
observation at the electron microscope. 
 
Figure 2. Microphotographs obtained in type 1 diabetic pancreatic samples after 
immunocytochemistry (A and B), semithin section analysis (C) or electron microscopy (D-
F). Mast cells are shown in the non-endocrine tissue (A: arrows, and D: indicated as MC), in 
the peri-insular region (B: arrows, and E: indicated as MC), and within islets (C: arrows, and 
F: indicated as MC)  
 
Figure 3. Microphotographs obtained from type 1 diabetic pancreatic samples after semithin 
section analysis (A) or electron microscopy (B-C) to evaluate morphological evidence of 
mast cell activation. A: A degranulated mast cell in the peri-insular region; B:  Mast cells 
showing signs of degranulation (arrows indicate mast cell granules and hollow granules in 
the cytoplasm of a mast cell); C: free mast cell granules (arrows) in close proximity of a beta 
cell. 
 
Figure 4. Effects of histamine exposure (100 µmol/l for 72h) on isolated human islets (A-C) 
and INS-1E cells (D,E). A: No difference in the expression of cleaved (active) caspases 9 
and 3 in human islets either not exposed (Control) or exposed to histamine; B: Proportion of 
beta cells with signs of apoptosis in control human islets and human islets exposed to 
caspase inhibitor alone, histamine alone or caspase inhibitor plus histamine; *: p < 0.05 
(Bonferroni corrected) vs control islets and islets exposed to caspase inhibitor alone; C: 
Gene expression by qPCR of apoptosis induced factor (AIF; expression corrected for β-
actin) in control islets and islets exposed to histamine; *: p < 0.05 by the Student’s t-test; D: 
Mitochondrial complex 1 enzymatic activity in INS-1E cells exposed or not to histamine; *: 
p < 0.05 by the Student’s t-test; E: Cytofluorimetric analysis of the mitochondrial membrane 
potential in INS-1E cells exposed or not to histamine.  
